SGLT2 inhibitors are recognized for their cardioprotective and nephroprotective properties, thus making them particularly advantageous for patients at high risk of cardiovascular diseases and those suffering from chronic kidney disease (Zelniker et al., 2019; Rahman et al., 2023). Here, SLC5A2 is linked to cardiovascular disorder.